DP
EPRS

Dearborn Partners’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Dearborn Partners’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-20,000
Closed -$179K – 296
2015
Q1 		$179K Buy
+20,000
New +$161K 0.02% 286

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

Dearborn Partners's EPRS Position: Q2 2015 in Review

Dearborn Partners sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2015, closing a stake of 20,000 shares — an estimated $179K sold.

Dearborn Partners first reported a position in EPRS in Q1 2015 and held it in 1 quarter. The position peaked at $179K in Q1 2015. 41 funds tracked by Wall St. Rank hold EPRS as of Q2 2015.

  • Dearborn Partners reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2015 after selling out during the quarter.
  • Dearborn Partners sold 20,000 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2015, an estimated $179K.
  • Dearborn Partners first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 1 quarter.
  • Dearborn Partners's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $179K in Q1 2015.
  • 41 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2015.

Based on Dearborn Partners's 13F filing for Q2 2015, filed 13 Aug 2015.